Filing Flows › Mannkind (MNKD) › Guidance & outlook
Mannkind (MNKD) guidance and outlook
Mannkind's 10-Q filed Nov 5, 2026 makes 12 forward-looking statements.
Guidance and outlook
Forward-looking statements, 10-Q filed Nov 5, 2026
- With deep expertise in drug-device combinations, we aim to deliver therapies designed to fit seamlessly into daily life.
- Our expectation is that Furoscix ReadyFlow will become the dominant dosage form of the product; its adoption rate during the remainder of 2026 will be a key factor to help us evaluate the extent to which there is a continuing market for the Furoscix on-body infusor.
- We expect to supply Cipla with additional product in accordance with the annual purchase commitments in our supply agreement.
- We expect margins to improve as Furoscix ReadyFlow is adopted into the market.
- In combination with our cash, cash equivalents and investments on hand, we believe that these sources of revenue will allow us to meet our liquidity needs over the next 12 months and in the longer term.
- As of September 30, 2026, management does not expect a payout under this milestone.
- In addition to the above, we also expect to have material cash requirements relating to paying our employees and consultants, professional services fees, marketing expenses, manufacturing expenditures, and clinical trial expenses.
- In addition, we make substantial and often long-term investments in our supply chain in order to ensure we have enough inventory and drug product to meet current and future revenue forecasts, as well as clinical trial needs.
- We believe that we will be able to meet our near-term liquidity needs based on our cash, cash equivalents and investments on hand, sales of Afrezza, Furoscix and V-Go, royalties and manufacturing revenue from the production and sale of Tyvaso DPI and, if necessary, borrowings under the Blackstone Credit Facility, as well as through debt or equity financing, for our long-term liquidity needs.
- We expect to continue to incur expenditures for the foreseeable future in support of our manufacturing operations, sales and marketing costs for our products and development costs for other product candidates in our pipeline.
- To date, we have been able to timely make required interest payments under our outstanding indebtedness, including the total principal amount of outstanding borrowings of $325.0 million, but we cannot guarantee that we will be able to do so in the future.
- If we fail to repay our outstanding indebtedness when required, we will be in default under the applicable instrument for such indebtedness and may also suffer an event of default under the terms of other borrowing arrangements that we may enter into from time to time.
Mannkind's latest quarter
Mannkind, Q3 2026: revenue $102M (+24% year over year), operating margin -2.1%, net loss $23.2M, operating cash flow −$34.5M. The chart follows the revenue to costs, profit and cash.
Questions
What does Mannkind expect?
With deep expertise in drug-device combinations, we aim to deliver therapies designed to fit seamlessly into daily life. Our expectation is that Furoscix ReadyFlow will become the dominant dosage form of the product; its adoption rate during the remainder of 2026 will be a key factor to help us evaluate the extent to which there is a continuing market for the Furoscix on-body infusor. We expect to supply Cipla with additional product in accordance with the annual purchase commitments in our supply agreement.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.